Related references
Note: Only part of the references are listed.Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
Heather L. McArthur et al.
CANCER (2011)
Breast Conservation Therapy in Patients With Stage T1-T2 Breast Cancer Current Challenges and Opportunities
Carlos A. Perez
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
ESTROGEN/PROGESTERONE RECEPTOR NEGATIVITY AND HER2 POSITIVITY PREDICT LOCOREGIONAL RECURRENCE IN PATIENTS WITH T1a,bN0 BREAST CANCER
Jeffrey M. Albert et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Management of small HER2-positive breast cancers
Susana Banerjee et al.
LANCET ONCOLOGY (2010)
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
S. M. Tovey et al.
BRITISH JOURNAL OF CANCER (2009)
Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer
Giuseppe Curigliano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab for Patients With Axillary-Node-Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
Marc Spielmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller
Ana M. Gonzalez-Angulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M. Untch et al.
ANNALS OF ONCOLOGY (2008)
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
Gustavo A. Viani et al.
BMC CANCER (2007)
Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities
Suleiman Massarweh et al.
CLINICAL CANCER RESEARCH (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
M De Laurentiis et al.
CLINICAL CANCER RESEARCH (2005)
Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies
SK Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
